The proposed financing of the Social Security Act (PLFSS) for 2016 is currently in preparation with the first arbitration expected to take place in the coming days. It is foreseen that there will be further price declines of up to 4%.
At the last meeting of the Generics Monitoring Committee on the 18th June, The Economic Committee for Health Products (CEPS) presented its intentions. These included: the addition of a new therapeutic class, those of calcium antagonists in the process of “convergence” in the prices of originator specialties than their generic; the introduction of new flat rates of liability (TFR), especially on the Plavix; and generic price cuts envisaged in terms of volume discounts granted to pharmacies by laboratories.
The Federation of Pharmaceutical Trade Unions of France (FSPF) has already warned “that it will oppose any decision to massively reduce prices without compensation, which could undermine the pharmaceutical network as a whole, and with it the proximity model which patients are attached.”
The full article can be read here (Available in French)